Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Overview
2.1.1 Rheumatoid Arthritis
2.1.2 Osteoarthritis
2.1.3 Osteoporosis
2.1.4 Systemic Lupus Erythematosus
2.1.5 Psoriatic Arthritis
2.2 Etiology
2.3 Pathophysiology
2.3.1 Rheumatoid Arthritis
2.3.2 Osteoarthritis
2.3.3 Osteoporosis
2.3.4 Systemic Lupus Erythematosus
2.3.5 Psoriatic Arthritis
2.4 Epidemiology Patterns and Forecasts – Prevalence and Patient Segmentation
2.4.1 Rheumatoid Arthritis
2.4.2 Osteoarthritis
2.4.3 Osteoporosis
2.4.4 Systemic Lupus Erythematosus
2.4.5 Psoriatic arthritis
2.5 Treatment
2.5.1 Rheumatoid Arthritis
2.5.2 Osteoarthritis
2.5.3 Osteoporosis
2.5.4 Systemic Lupus Erythematosus
2.5.5 Psoriatic Arthritis
3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) – AbbVie
3.3 Enbrel (etanercept) – Amgen
3.4 Simponi (golimumab) – Johnson & Johnson
3.5 Remicade (infliximab) – Johnson & Johnson
3.6 Rituxan (rituximab) – Roche
3.7 Stelara (ustekinumab) – Johnson & Johnson
3.8 Cosentyx (secukinumab) – Novartis
3.9 Prolia (denosumab) – Amgen
3.1 Orencia (abatacept) – Bristol-Myers Squibb
3.11 Actemra (tocilizumab) – Roche
3.12 Benlysta (belimumab) – GlaxoSmithKline
3.13 Forteo (teriparatide) – Eli Lilly
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecule Types in the Pipeline
4.4 Molecular Targets in the Pipeline
4.5 Clinical Trials Landscape
4.5.1 Clinical Trial Failure Rates
4.5.2 Clinical Trial Duration
4.5.3 Clinical Trial Size
4.5.4 Cumulative Clinical Program Size
4.6 Assessment of Key Pipeline Products
4.6.1 Upadacitinib tartrate – AbbVie
4.6.2 Filgotinib – Gilead Sciences
4.6.3 Lenabasum – Corbus Pharmaceuticals
4.6.4 Evenity (romosozumab) – Amgen / UCB / Astellas
4.6.5 Avacopan – ChemoCentryx
4.6.6 Pegadricase – Selecta Biosciences
4.6.7 Anifrolumab – AstraZeneca
5 Multi-scenario Market Forecast to 2024
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Products Acting on Tumor Necrosis Factor-Alpha
5.3.2 Products Acting on Interleukins and Interleukin Receptors
5.3.3 Products Acting on Protein Kinases
5.3.4 Products Acting on Cell Surface Antigens
5.3.5 Products Acting on Hormones and Hormone Receptors
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 AbbVie
6.1.2 Amgen
6.1.3 Johnson & Johnson
6.1.4 Novartis
6.1.5 Pfizer
6.1.6 Roche
6.1.7 Eli Lilly
6.1.8 Bristol-Myers Squibb
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication and Value
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type, Molecular Target and Value
7.1.5 Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication and Value
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Molecular Target and Value
7.2.5 Co-development Deals with Disclosed Values
8 Appendix
8.1 References
8.2 Figures of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer